Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 5/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 5/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 5/20 | 0.34 |
| ▸ | GABRA3 | P34903 | 5/20 | 0.34 |
| ▸ | GABRA2 | P47869 | 5/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.33 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.33 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.33 |
| ▸ | CFB | P00751 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.32 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | GPR6 | P46095 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL897916 | 0.90 | PIN1 (0.38) | L3MBTL1CFBPIN1ALKGSK3B | |
| SCHEMBL897523 | 0.80 | MAPT (0.36) | L3MBTL1ARGPR6 | |
| SCHEMBL1703702 | 0.78 | PIN1 (0.35) | L3MBTL1CFBPIN1ALKGSK3B | |
| SCHEMBL23639626 | 0.76 | L3MBTL1 (0.39) | L3MBTL1GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL31507391 | 0.74 | L3MBTL1 (0.37) | L3MBTL1GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL24676748 | 0.74 | L3MBTL1 (0.37) | L3MBTL1GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL6216846 | 0.73 | GABRA1 (0.43) | L3MBTL1GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL898346 | 0.72 | L3MBTL1 (0.36) | L3MBTL1GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL31540875 | 0.72 | L3MBTL1 (0.36) | L3MBTL1GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL14784928 | 0.71 | GABRA1 (0.42) | L3MBTL1GABRA1GABRG2GABRB3GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230142119-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-11 | — | — | US | disclosed |
| US-20230142119-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-11 | — | — | US | disclosed |
| US-20220306578-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-09-29 | — | — | US | disclosed |
| US-20220306578-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-09-29 | — | — | US | disclosed |
| EP-3613729-A1 | TETRACYCLIC COMPOUNDS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2020-02-26 | — | — | EP | disclosed |
| EP-3345903-B1 | TETRACYCLIC COMPOUNDS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2019-10-09 | — | — | EP | disclosed |
| EP-3345903-A1 | TETRACYCLIC COMPOUNDS | Chugai Seiyaku Kabushiki Kaisha (JP) | 2018-07-11 | — | — | EP | disclosed |
| EP-2975024-B1 | TETRACYCLIC COMPOUNDS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2018-03-28 | — | — | EP | disclosed |
| US-20160340308-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-11-24 | — | — | US | disclosed |
| US-9440922-B2 | Tetracyclic compound | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-09-13 | — | — | US | disclosed |
| EP-2441753-B1 | TETRACYCLIC COMPOUND | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2016-03-30 | — | — | EP | disclosed |
| EP-2975024-A1 | TETRACYCLIC COMPOUNDS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-01-20 | — | — | EP | disclosed |
| US-9126931-B2 | Tetracyclic compound | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-09-08 | — | — | US | disclosed |
| US-20150150845-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-06-04 | — | — | US | disclosed |
| EP-2441753-A1 | TETRACYCLIC COMPOUND | Chugai Seiyaku Kabushiki Kaisha (JP) | 2012-04-18 | — | — | EP | disclosed |
| US-20120083488-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230142119-A1 | TETRACYCLIC COMPOUND | ALK, TTR, ACVR1 | L3MBTL1 200/4885GABRA1 1413/4885GABRG2 1898/4885 |
| US-20120083488-A1 | TETRACYCLIC COMPOUND | ALK, TTR, ACVR1 | L3MBTL1 200/4885GABRA1 1413/4885GABRG2 1898/4885 |
| US-20220306578-A1 | TETRACYCLIC COMPOUND | ALK, TTR, ACVR1 | L3MBTL1 200/4885GABRA1 1413/4885GABRG2 1898/4885 |
| US-20160340308-A1 | TETRACYCLIC COMPOUND | ALK, TTR, ACVR1 | L3MBTL1 200/4885GABRA1 1413/4885GABRG2 1898/4885 |
| US-20150150845-A1 | TETRACYCLIC COMPOUND | ALK, TTR, ACVR1 | L3MBTL1 200/4885GABRA1 1413/4885GABRG2 1898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.